1642. A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug-Resistant (MDR) Mycobacterium abscessus (Mab)

Lignende værker

• 1385. Mechanism-Based, In Vitro Inhibition of Mycobacterium abscessus: Assessing β-Lactam Therapy
  af: Dousa, Khalid M, et al.
  Udgivet: (2019)
• Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
  af: Shapiro, Adam B., et al.
  Udgivet: (2021)
• First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus
  af: Sayed, Alaa R. M., et al.
  Udgivet: (2020)
• Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations
  af: Kurz, Sebastian G., et al.
  Udgivet: (2013)
• Inhibition of the β-Lactamase Bla(Mab) by Avibactam Improves the In Vitro and In Vivo Efficacy of Imipenem against Mycobacterium abscessus
  af: Lefebvre, Anne-Laure, et al.
  Udgivet: (2017)